CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Interest and Dividend Income	129.09	130.45	155.79	91.88
Total Interest Expense	0.12	0.12	-	-
Net Interest Income	128.97	130.33	155.79	91.88
Brokerage Commission	56.89	49.04	30.68	8.5
Other Revenue	231.55	209.6	202.03	287.82
Revenue	417.4	388.97	388.5	388.21
Revenue Growth (YoY)	11.41%	0.12%	0.08%	-
Salaries & Employee Benefits	32.59	32.59	29.41	30.02
Cost of Services Provided	370.03	372	337.21	289.76
Other Operating Expenses	-0.53	-1.59	-0.6	-1.84
Total Operating Expenses	402.09	402.99	366.03	317.94
Operating Income	15.31	-14.02	22.47	70.26
Currency Exchange Gains	1.97	1.97	-2.3	5.51
EBT Excluding Unusual Items	17.28	-12.05	20.18	75.77
Other Unusual Items	-	-	-	1.41
Pretax Income	17.28	-12.05	20.18	65.69
Income Tax Expense	17.67	13.82	16.14	32.21
Earnings From Continuing Ops.	-0.38	-25.87	4.04	33.47
Earnings From Discontinued Ops.	2.69	2.69	1.78	16.6
Net Income to Company	2.31	-23.18	5.82	50.08
Minority Interest in Earnings	0.51	0.49	0.25	-
Net Income	2.82	-22.69	6.07	50.08
Preferred Dividends & Other Adjustments	-570.92	495.09	340.08	51.41
Net Income to Common	573.74	-517.78	-334.01	-1.33
Net Income Growth	-	-	-87.88%	-
Shares Outstanding (Basic)	139	139	138	134
Shares Outstanding (Diluted)	139	139	138	134
Shares Change (YoY)	237.68%	0.63%	2.58%	-
EPS (Basic)	4.12	-3.73	-2.42	-0.01
EPS (Diluted)	4.12	-3.73	-2.42	-0.01
Free Cash Flow	-	182.8	466.05	-62.76
Free Cash Flow Per Share	-	1.32	3.38	-0.47
Operating Margin	3.67%	-3.60%	5.79%	18.10%
Profit Margin	137.45%	-133.12%	-85.97%	-0.34%
Free Cash Flow Margin	-	47.00%	119.96%	-16.17%
Effective Tax Rate	102.21%	-	79.99%	49.04%
Revenue as Reported	418.66	390.23	389.6	388.33

Updated Apr 25, 2025. Source: S&P Global Market Intelligence. Capital Markets template. Financial Sources.